Medtronic Survey Finds Pandemic Creating Far-reaching & Negative Impacts on Those with Chronic Back or Leg Pain

Medtronic this morning reported a new survey they commissioned and conducted by public opinion research firm The Harris Poll, finds nearly half (44%) of current chronic back and leg pain sufferers have experienced care delays during the COVID-19 pandemic, despite 87% reporting that their pain has not improved or even worsened since the pandemic began in March 2020.

Medtronic Figure 1


Medtronic Harris Poll Survey

The national survey, “Painful Pandemic: How a Healthcare System Under Strain Impacts Chronic Pain Patients,” of 810 U.S. adults who currently experience chronic back or leg pain finds far-reaching impacts of this debilitating condition on patient lifestyle, everyday activities, and mental state, further exacerbated by the pandemic’s impact on stressed health systems and the ability of patients to seek timely care.

Of those who report worsening chronic pain during the pandemic, more than half (52%) cite challenges in receiving appropriate medical care as a contributing factor. Additionally, 44% say since the pandemic began, they have experienced care delays, including postponed, rescheduled, or canceled appointments or procedures for their pain. Of those who proactively postponed their medical care, more than half (55%) cited COVID-19 fears as a contributing factor.

Pain significantly impacts daily life

Most people currently living with chronic back or leg pain report numerous detrimental physical and mental impacts. When listing physical challenges associated to living with chronic pain, sleep, exercise habits, sense of mobility/function, and ability to enjoy hobbies are aspects of life most negatively impacted (see figure 1). Chronic back or leg pain sufferers under age 55 are more likely than those 55+ to report that their ability to work has been impacted (36% vs. 22%, respectively), while those over age 55 are more likely than those age 35-54 to say their sense of mobility/function has been impacted (58% vs. 46%, respectively).

In addition, most (66%) report that their mental health has been negatively impacted and list feelings of frustration, annoyance, exhaustion, and depression (see figure 2). Surveyed patients also say that it is harder to enjoy spending time with their family (67%).

As a result, the overwhelming majority (90%) of sufferers say they wish there were more treatment options available to manage their pain. While most are aware of traditional treatment options like physical therapy and oral medications, far fewer are familiar with options such as targeted drug delivery (38%) or spinal cord stimulation (34%). On average, those who have seen or talked to a healthcare provider, about their chronic back or leg pain, first did so seven years ago, while 38% of current chronic back or leg pain sufferers say they have never been referred to a pain specialist physician for their chronic pain.

“This data bears out what we’ve heard from our clinician customers and patients for two years – the pandemic has been especially hard on those with chronic pain,” said Charlie Covert, vice president and general manager, Pain Therapies within the Neuromodulation business, which is part of the Neuroscience portfolio at Medtronic. “There is a tangible human cost to deferred procedures and delayed care. As COVID-19 hopefully begins its transition to a more endemic disease, we expect many of these patients to urgently seek relief through new or more effective treatment modalities. Our survey demonstrated that an overwhelming majority want more treatment options, yet awareness of spinal cord stimulation and targeted drug delivery options remains relatively low. That represents an opportunity to educate patients about the full range of options available to help alleviate their pain.”

For more information about the survey, visit here.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy